Prosecution Insights
Last updated: November 04, 2026
Application No. 19/028,179

Use of Bordetella Strains for the Treatment of Chronic Obstructive Pulmonary Disease

Non-Final OA §102§112§DOUBLEPATENT
Filed
Jan 17, 2025
Priority
Jul 22, 2022 — EU 22306105.2 +1 more
Examiner
DEVI, SARVAMANGALA
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Université De Lille
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
1y 6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
580 granted / 884 resolved
+5.6% vs TC avg
Strong +56% interview lift
Without
With
+55.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
53 currently pending
Career history
937
Total Applications
across all art units

Statute-Specific Performance

§101
7.2%
-32.8% vs TC avg
§103
17.7%
-22.3% vs TC avg
§102
25.5%
-14.5% vs TC avg
§112
43.6%
+3.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 884 resolved cases

Office Action

§102 §112 §DOUBLEPATENT
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Preliminary Amendment 1) Applicants’ election filed 08/05/26 in response to the species election requirement mailed 06/24/26 is acknowledged. Election 2) Applicants’ election filed Species election filed 08/05/26 in response to the species election requirement mailed 06/24/26. Applicants have elected, with traverse, the Bordetella pertussis strain species comprising a mutated ptx gene, a deleted dnt gene, and a heterologous ampG gene and the additional pertactin deficient mutation species. Applicants’ traversal is on the basis that the species are so closely related that the additional searches would not create an undue burden. Applicants’ argument has been carefully considered, but is not persuasive. In addition to the search burden for searching each of the identified divergent Bordetella species carrying different types and combinations of mutations, there is also an examination burden under different statutes and double patenting. Accordingly, the species election requirement as set forth is proper, is maintained, and is hereby made FINAL. Status of Claims 3) Claim 14 has been canceled via the preliminary amendment filed 08/05/26. Claims 1-13 are pending and are under examination. Replacement Drawing(s) 4) The replacement drawings filed 03/17/25 are acknowledged. Priority 5) The instant AIA application, filed 01/17/25, is a continuation of PCT/EP2023/070301 filed 07/21/2023, which claims priority to application 22306105.2 filed 07/21/2023. Objection(s) to Specification 6) The instant specification is objected to for the following reason(s): The use of trademark recitations has been noted in the instant specification. For example, see paragraph [0055] for “Alexa 700”. All trademark recitations should be CAPITALIZED wherever they appear. See M.P.E.P 608.01(V) and Appendix l. Although the use of trademarks is permissible in patent applications, the propriety nature of the marks should be respected and every effort made to prevent their use in any manner, which might adversely affect their validity as trademarks. It is suggested that Applicants examine the whole specification to make similar corrections to trademark recitations, wherever such recitations appear. Rejection(s) under 35 U.S.C § 112 (pre-AIA ), First Paragraph 7) The following is a quotation of 35 U.S.C § 112(a): (a) IN GENERAL. - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C § 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out the invention. 8) Claims 1-6 and 8-13 are rejected under 35 U.S.C § 112(a) or 35 U.S.C § 112 (pre-AIA ), first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection. The purpose of the written description requirement is ‘to ensure that the inventor had possession, as of the filing date of the application relied on, of the specific subject matter later claimed by him. The analysis of whether the specification complies with the written description requirement calls for the Office to compare the scope of the claims with the scope of the description in the as-filed specification to determine whether Applicants have demonstrated possession of the full scope of the claimed method at the time of the invention. An analysis of the scope of the claimed invention indicates the following. Claim 1 is representative of the instant invention. Claim 1 is drawn to a method of treating chronic obstructive pulmonary disease (COPD) in a patient in need thereof comprising administering a therapeutically effective amount of a mutated Bordetella strain comprising a mutated pertussis toxin (ptx) gene, a deleted dermonecrotic (dnt) gene, and a heterologous ampG gene. What precisely is a ‘dermonecrotic (dnt) gene’ in a Bordetella strain is not described. The art of Bordetella does not recognize a ‘dermonecrotic (dnt) gene’. The as-filed specification defines the term “treatment” or “treat” as referring to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of patients at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse. See section [024] of the as-filed specification. While the mutated Bordetella strain administered in the method of claim 10 is required to be attenuated, the mutated Bordetella strain administered in the method of the rest of the claims is not and therefore encompasses wild-type pathogenic Bordetella strains. While the Bordetella strain in the method of claim 11 is required to be a live vaccine, the mutated Bordetella strain administered in the method of rest of the claims is not. The mutated Bordetella strain administered in the method of claim 9 is also deficient for pertactin. The recited mutated ptx gene in the mutated Bordetella strain genus includes deletion of the functional pertactin gene, truncations in the ptx gene, and having one or more specific point mutations, substitutions, and/or insertions etc in the ptx gene. Likewise, the deficiency for pertactin in a Bordetella strain includes having deletion of the functional pertactin gene, truncations in their pertactin gene, and having one or more specific point mutations, substitutions and/or insertions etc in the pertactin gene. Although the elected mutated Bordetella strain species is the mutated Bordetella pertussis as claimed in claims 6-7, the broadly recited mutated Bordetella strain in claim 1 represents a huge genus of live and killed, attenuated and non-attenuated antigenically and genetically divergent species within the entire large genus of Bordetella including all non-B. pertussis species of Bordetella, for example, Bordetella parapertussis, Bordetella bronchiseptica, Bordetella holmesii, Bordetella trematum, Bordetella ansorpii, Bordetella avium, Bordetella hinzii, Bordetella petrii etc. See for example the teachings of Srigley et al. Clin. Microbiol, Newsletter 37: 61-65, 2015. The genetically and antigenically divergent Bordetella bacteria strain species encompassed within the huge genus of the mutated Bordetella bacteria strain genus that are live or killed (inactivated) and/or attenuated or non-attenuated (wild-type) Bordetella bacteria strains having a mutated ptx gene, a deleted dermonecrotic (dnt) gene, and a heterologous ampG gene, with or without having a deficiency in pertactin, broadly include, for example: (i) Bordetella ansorpii species deficient or non-deficient in pertactin and having a deleted non-B. pertussis dermonecrotic dnt gene; (ii) Bordetella holmesii species deficient or non-deficient in pertactin and having a deleted non-B. pertussis dermonecrotic dnt gene; (iii) Bordetella hinzii species deficient in non-B. pertussis pertactin and having a deleted Bordetella trematum dermonecrotic dnt gene etc, each of which is required to have the following functional properties: (a) the therapeutic capacity to treat COPD including a moderate COPD, a severe COPD, and a very severe COPD; (b) the capacity to prevent progression of COPD in a patient including prevention of progression of COPD from one stage to a subsequent stage in the GOLD classification; (c) the capacity to serve as a live vaccine (claim 9); and (d) the capacity to be optimally or acceptably attenuated (claim 10). However, at the time of the invention, Applicants were not in possession of the full scope of the variant Bordetella genus having said functions and the full scope of the invention as claimed. The written description requirement can be met by describing the claimed subject matter to a person skilled in the art using sufficiently detailed, relevant identifying characteristics such as functional characteristics, and correlating those functional characteristics with a disclosed structure. See Enzo Biochem v. Gen-Probe, 323 F.3d 956, 964, 967, 968 (Fed. Cir. 2002). Sufficient description to show possession of the genus may be achieved by means of disclosure of a representative number and variety of the administered live and non-live as well as attenuated and non-attenuated, i.e., wild type, mutated Bordetella strain species encompassed within the huge genus that comprise a pertussis toxin (ptx) gene that is mutated via any or any combination of mutation species, i.e., deletion, point mutation, insertion, genetic inactivation etc, a deleted dermonecrotic (dnt) gene, and a heterologous ampG gene. MPEP § 2163.02 states: ‘an objective standard for determining compliance with the written description requirement is, does the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed’. The courts have decided that the purpose of the ‘written description’ requirement is broader than to merely explain how to ‘make and use’; the applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. In the instant case, the full breadth of the of the variant genus and of the claims does not meet the written description provision of 35 U.S.C § 112(a). At the time of the invention, the only mutated Bordetella strain species that Applicants were in possession of was the live attenuated Bordetella pertussis strain species BPZE1 strain having the accession number CNCM I-3585 carrying its B. pertussis ptx gene specifically mutated and its B. pertussis dnt gene deleted, and having its homologous or endogenous ampG gene replaced with a heterologous ampG gene resulting in expression of its TCT toxin having less than 1% residual TCT activity. The structure of said Bordetella pertussis strain BPZE1 strain species having the accession number CNCM I-3585 was correlated with the ability to limit COPD outcomes in mice by decreasing the chronic smoke (CS)-induced inflammation and restoring partially the CS-induced lung function alteration. See ‘Conclusion’ on page 18. Unlike this Bordetella pertussis BPZE1 strain species, the enormous species encompassed within the broad mutated Bordetella strain genus of rest of the claims are not required to have a mutated or deleted TCT gene. There is no showing of possession at the time of the invention of a method of treating COPD disease in a patient in need thereof comprising administering a therapeutically effective amount of any mutated Bordetella strain comprising a mutated pertussis toxin (ptx) gene, a deleted dermonecrotic (dnt) gene, and a heterologous ampG gene and further being deficient for Bordetella pertactin. The BPZE1 strain having the accession number CNCM I-3585 further being deficient for Bordetella pertactin has not been correlated with the COPD-treating therapeutic and/or the COPD-preventing prophylactic capacity. Clearly, the species encompassed within the “mutated” Bordetella strain genus administered in the method of claims 1-6 and 8-13 are not limited to the BPZE1 strain of B. pertussis having the accession number CNCM I-3585 or to a non-BPZE1 strain of B. pertussis strain having all the identical mutation(s), deletion(s) and modification(s) as that of the BPZE1 strain of B. pertussis having the accession number CNCM I-3585. Instead, the genus of the mutated Bordetella strain administered in the claimed method encompassing live and non-live and/or attenuated and non-attenuated B. pertussis and non-B. pertussis Bordetella strain species is extraordinarily huge and widely structurally and genetically divergent with regard to the types of mutations. The structure of a representative number and variety of the divergent species encompassed within this huge genus has not been correlated with the requisite therapeutic and prophylactic capacities to treat and prevent moderate, severe or very severe COPD and prevent progression of COPD in a patient from one stage to a subsequence stage in the GOLD classification as well as the capacity to remain live and/or attenuated. There was absolutely no predictability at the time of the invention that introducing the same or similar mutation(s), deletion(s) and ampG replacement(s) as those present in the BPZE1 B. pertussis strain species in to any of non-B. pertussis Bordetella strains would result in mutated Bordetella strain species having the COPD-treating and COPD-preventing functions as required by instant claims along with retaining the capacity to remain live and/or attenuated. This is critically important since unpredictability in the art is one of the factors that guide the written description inquiry. A specification adequately describes a claim directed to a genus only if the disclosure ‘indicates that the patentee has invented species sufficient to constitute the gen[us].’ See Enzo Biochem, 323 F.3d at 966, 63 USPQ2d at 1615; Noelle v. Lederman, 355 F.3d 1343, 1350, 69 USPQ2d 1508, 1514 (Fed. Cir. 2004) (Fed. Cir. 2004) (‘[A] patentee of a biotechnological invention cannot necessarily claim a genus after only describing a limited number of species because there may be unpredictability in the results obtained from species other than those specifically enumerated’). ‘A patentee will not be deemed to have invented species sufficient to constitute the genus by virtue of having disclosed a single species when .... the evidence indicates ordinary artisans could not predict the operability in the invention of any species other than the one disclosed.’ In re Curtis, 354 F.3d 1347, 1358, 69 USPQ2d 1274, 1282 (Fed. Cir. 2004). The disclosure of only one species (the live attenuated mutant Bordetella pertussis strain BPZE1 having specific mutations in specific parts of the specific genes in the instant case) encompassed within a genus adequately describes a claim directed to that genus only if the disclosure ‘indicates that the patentee has invented species sufficient to constitute the gen[us].’ See Enzo Biochem, 323 F.3d at 966, 63 USPQ2d at 1615; Noelle v. Lederman, 355 F.3d 1343, 1350, 69 USPQ2d 1508, 1514 (Fed. Cir. 2004) (Fed. Cir. 2004) (“[A] patentee of a biotechnological invention cannot necessarily claim a genus after only describing a limited number of species because there may be unpredictability in the results obtained from species other than those specifically enumerated”). In sum, the as-filed specification fails to show that the inventors possessed a sufficient number and variety of species to show they had “invented and disclosed the totality of the genus” and administered in the claimed method. The written description inquiry is case-specific and context-specific. It “depend[s] on the nature of the claimed invention and the knowledge of one skilled in the art at the time an invention is made and a patent application is filed.” Ariad, 560 at 1372. A number of factors guide the inquiry, including “the existing knowledge in the particular field, the extent and content of the prior art, the maturity of the science or technology, and the predictability of the aspect at issue.” Ariad, 560 at 1372. [Emphasis added]. According to MPEP 2163: The description needed to satisfy the requirements of …… 35 U.S.C § 112 “varies with the nature and scope of the invention at issue, and with the scientific and technologic knowledge already in existence.” Capon v. Eshhar, 418 F.3d at 1357, 76 USPQ2d at 1084. Patents and printed publications in the art should be relied upon to determine whether an art is mature and what the level of knowledge and skill is in the art. Evidence required to demonstrate possession of the invention is fact-specific and varies inversely with the maturity and predictability of the technology area. Inventions in “unpredictable” arts, as in the instant case, are subject to greater scrutiny under the written description requirement, and require a greater showing of possession than more predictable arts. In the instant case, the as-filed specification fails to show that the inventors possessed a sufficient number and variety of species to show they had “invented and disclosed the totality of the genus” and administered in the claimed method. Vas-Cath Inc. V. Mathukar, 19 USPQ2d 1111 states that Applicant "must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention, is for purposes of the 'written description' inquiry, whatever is now claimed." See page 1117. Furthermore, the written description provision of 35 U.S.C § 112 (pre-AIA ) is severable from its enablement provision. Applicants should note that written description requires more than a mere statement that something is part of the invention and a reference to a potential method for isolating it. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993) and Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. The specific description or guidance, not general description or guidance is needed. A mere idea or unsubstantiated function is insufficient for written description; characterization of a representative number of species in an unpredictable art, with their precise structure correlated with the requisite functions, is required in order to claim the broad genus. When a patent claims a genus using functional language to define a desired result, the specification must demonstrate that the applicant has made a generic invention that achieves the claimed result and do so by showing that the applicant has invented species sufficient to support a claim to the functionally-defined genus" (Capon v. Eshhar, 418 F.3d 1349 (Fed. Cir. 2005)) [Emphasis added]. Clearly, at the time of the invention neither the state of the art, nor the Applicants were in possession of a representative number and variety of mutated Bordetella strain species within the huge genus, the structure of which is correlated with the COPD-treating therapeutic functions and COPD-preventing prophylactic functions as required by instant claims along with the capacity to remain live and/or attenuated. Clearly, the specification does not describe the claimed embodiments in sufficient detail to convey to a person skilled in the art that Applicants were in possession of the full scope of the claimed invention at the time of filing. The scope of the claims is broader than what is justified by the adequate description within the as-filed specification. Instant claims do not meet the provision of 35 U.S.C § 112 (pre-AIA ), first paragraph. Rejection(s) under 35 U.S.C § 112(b) or (Pre-AIA ), Second Paragraph 9) The following is a quotation of 35 U.S.C § 112(b): (B) CONCLUSION --The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C § 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 10) Claims 1-13 are rejected under 35 U.S.C § 112(b) or pre-AIA , second paragraph, as being indefinite, for failing to particularly point out and distinctly claim the subject matter which inventor or a joint inventor, or for the pre-AIA the Applicants regard as the invention. (a) Claim 1 is ambiguous and indefinite in the limitation ‘dermonecrotic (dnt) gene’. What precisely is a ‘dermonecrotic (dnt) gene’ in a mutated Bordetella strain is not understood. The art of Bordetella does not disclose or recognize a ‘dermonecrotic (dnt) gene’. (b) Claims 3 and 4 are ambiguous, indefinite, and have an antecedence issue with regard to the limitations “a patient” and “COPD”. Since both claims depend from claim 1, it is suggested that Applicants replace said limitations with --the patient-- and --the COPD--. respectively. (c) Claim 5 is indefinite in having improper antecedence in the limitation “the Bordetella starting strain”. Claim 5 depends from claim, which does not recite a Bordetella starting strain. (d) Analogous rejection applies to the dependent claim 6 with regard to the limitation “the starting strain”. (e) Claim 1 is indefinite for being inconsistent with the dependent claims 3 and 4 with regard to the limitation “COPD”. For the purpose of distinctly claiming the subject matter, it is suggested that Applicants insert the limitation --(COPD)-- after the limitation “disease” in line 1 of claim 1. (f) Claim 8 is ambiguous and indefinite in the limitations: “mutations are introduced, such as pertactin deficient mutants”. This phrase makes no sense. The limitation “such as” is superfluous. Further, it is unclear how introduced ‘mutations’ are or can be ‘mutants’. One of ordinary skill in the art cannot understand in an ambiguous way that which is being claimed. (g) Claims 2-13, which depend directly or indirectly from claim 1, are also rejected as being indefinite due to the indefiniteness identified supra in the base claim. Claim(s) Interpretation 11) As per the express definition of the claim limitation “treatment” or “treat” provided at section [024] of the as-filed specification, the instantly claimed method of treating COPD in a patient in need thereof is interpreted as including a prophylactic or preventive treatment of patients at risk of contracting COPD or patients who ultimately may acquire COPD, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of COPD. Double Patenting Rejection(s) 12) The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. 13) Claims 1-7 and 10-13 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-6 of US patent 9526778 B2 (‘778 patent) as evidenced by Liao et al. International J. Chron. Obstruct. Pulmonary Dis. 17: 2253-2261, 14 September 2022. Although the conflicting claims are not identical, they are not patentably distinct from each other. The method claimed in the claims of the ‘778 patent of administering intranasally to a mammalian subject having lung immunopathology due to influenza A virus infection or is at increased risk of developing said infection a sufficient amount of a live attenuated, mutated Bordetella pertussis strain BPZE1, i.e., the instantly recited BPZE1 strain having the accession number CNCM I-3585, falls within the scope of instant claims. The administered BPZE1 strain comprises a mutated pertussis toxin(ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene. That the mammalian subject administered with the BPZE1 mutant strain of B. pertussis qualifies as one who is at risk of developing, at risk of contracting COPD, or who ultimately may acquire COPD is inherent from the disclosure of the prior art in light of what is well known in the art. For instance, the evidentiary reference of Liao et al. identified subjects with influenza A virus infection or who are at risk of developing said infection as being at significantly higher risk of contracting COPD. See at least the first full paragraph under ‘Discussion’ on page 2255. Clearly, the prior art method meets the structural requirement of instant claims and thus reads on instant claims. The claim limitations “method ..... for preventing .....” in claims 3 and 4 represents the intended use of the claimed method and is of no significance to claim construction. Notice Re Prior Art Available under Both Pre-AIA and AIA In the event the determination of the status of the application as subject to AIA 35 U.S.C § 102 and 35 U.S.C § 103 (or as subject to pre-AIA 35 U.S.C § 102 and 35 U.S.C § 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection would be the same under either status. Rejection(s) under 35 U.S.C § 102 14) The following is a quotation of the appropriate paragraphs of 35 U.S.C § 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. 15) Claims 1-7 and 10-13 are rejected under 35 U.S.C § 102(a)(1) as being anticipated by US 9526778 B2 (‘778) as evidenced by Liao et al. International J. Chron. Obstruct. Pulmonary Dis. 17: 2253-2261, 14 September 2022. The ‘778 patent disclosed a method of administering a sufficient amount of the live attenuated, mutated Bordetella pertussis BPZE1 strain, i.e., the instantly recited BPZE1 strain having the accession number CNCM I-3585, to a mammalian subject in need thereof, or having lung immunopathology due to influenza virus infection or influenza A virus infection or is at increased risk of developing infection with influenza A virus. The mutated Bordetella pertussis strain BPZE1 so administered comprised a mutated pertussis toxin(ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene. The administering was by nasal or intranasal route or via aerosol. See claims; paragraph bridging columns 7 and 8; 1st full paragraph of columns 8 and 18; 2nd full paragraph of column 18; and 6th full paragraph in column 6. That the mammalian subject administered with the BPZE1 mutant strain of B. pertussis qualifies as one who is at risk of developing, at risk of contracting COPD, or who ultimately may acquire COPD is inherent from the disclosure of the prior art in light of what is well known in the art. For instance, Liao et al. identified subjects with influenza A virus infection or who are at risk of developing said infection as being at significantly higher risk of contracting COPD. See at least the first full paragraph under ‘Discussion’ on page 2255. Clearly, the prior art method meets the structural requirement of instant claims and thus reads on instant claims. The claim limitations “method ..... for preventing .....” in claims 3 and 4 represents the intended use of the claimed method and is of no significance to claim construction. Claims 1-7 and 10-13 are anticipated by US 9526778 B2 (‘778). The reference of Liao et al. is not used as a secondary reference in combination with the reference of US 9526778 B2 (‘778), but rather is used to show that every element of the claimed subject matter is disclosed by US 9526778 B2 (‘778) with the unrecited limitation(s) being inherent as evidenced by the state of the art. See In re Samour 197 USPQ 1 (CCPA 1978). Relevant Art 16) The art made of record and not relied upon in any of the rejections is considered pertinent to Applicants’ disclosure: l WO 2007/104451 (Applicants’ IDS) disclosed the live attenuated triple mutant B. pertussis strain BPZE1 that is deposited at the CNCM with the accession number CNCM 1-3585. WO 2007/104451 taught that the mutations introduced into BPZE1 resulted in ‘drastic attenuation’ and allowed the bacteria to colonize and persist. See page 11. Correspondence 17) Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (571) 272-0854. A message may be left on the Examiner’s voice mail system. The Examiner is on a flexible work schedule, however she can normally be reached Monday to Friday from 8.00 a.m. to 4.00 p.m. (EST). If attempts to reach the Examiner by telephone are unsuccessful, Examiner's Supervisor, Jeffrey Stucker, can be reached at (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned (571) 273-8300. 18) Information regarding the status of an application may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center or Private PAIR to authorized users only. Should you have questions about access to Patent Center or the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, Applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. /S. DEVI/ S. Devi, Ph.D.Primary Examiner Art Unit 1645 October, 2026
Read full office action

Prosecution Timeline

Jan 17, 2025
Application Filed
Oct 16, 2026
Non-Final Rejection mailed — §102, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758624
INDUSTRIAL PRODUCTION METHOD FOR STAPHYLOCOCCUS AUREUS VACCINE
2y 9m to grant Granted Oct 13, 2026
Patent 12746261
PROBIOTIC BACILLUS COMPOSITIONS AND METHODS OF USE
3y 6m to grant Granted Sep 29, 2026
Patent 12697379
PEGYLATED TETANUS NEUROTOXINS AND TREATMENT OF HYPOTONIA
5y 6m to grant Granted Aug 04, 2026
Patent 12699090
DIAGNOSTIC REAGENTS
4y 10m to grant Granted Aug 04, 2026
Patent 12691167
PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING KLEBSIELLA PROTEINS AND METHODS OF USE
2y 7m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+55.6%)
3y 4m (~1y 6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 884 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month